LINCOLNSHIRE, Ill., November 22, 2005 – Takeda Pharmaceuticals North America, Inc. (TPNA), announced today that Jeanine Jiganti joined the company as chief compliance officer. Her responsibilities include advising senior management of compliance and regulatory issues and promoting compliance with applicable laws and company policies through detection and prevention. In this role, Jiganti joins the executive team and will work closely with Takeda’s research company – Takeda Global Research and Development Center, Inc.
“Having more than 19 years of advising experience from a variety of perspectives, including compliance and ethical issues, Jeanine brings a solid background and extensive knowledge to this position and the Takeda team,” said Mark Booth, president of Takeda Pharmaceuticals North America. “We’re pleased she is joining us to provide counsel on the many compliance requirements facing pharmaceutical companies today and to help us continue to uphold our company’s strong values.”
Jiganti joins Takeda from the State of Illinois, where she was a member of the senior management team as the general counsel and ethics officer for the Department of Commerce and Economic Opportunity. There, she provided counsel regarding conflicts of interest and ethical issues for an agency that creates and attracts jobs to the state through grants and incentive programs. Previously, Jiganti was Vice President of Legal handling Regulatory Affairs for a Fortune 500 company, general counsel at Near North Insurance Brokerage and a lawyer at top law firms in Chicago and New York.
In both the public and private sector during her 19 years of experience, Jiganti has drafted legislation, conducted programs that significantly improved business operations and advised senior management on a variety of regulatory and compliance issues.
Jiganti earned a bachelor’s degree from the University of Colorado and a law degree from Loyola University of Chicago School of Law.
Takeda Pharmaceuticals North America, Inc.
Based in Lincolnshire, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets oral diabetes, sleep and cholesterol lowering treatments, and through the Takeda Global Research & Development Center, Inc. the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit www.tpna.com .
# # #